[1]曾利文,陈 静,张 晔,等.多囊卵巢综合征患者的糖代谢特点分析[J].医学信息,2019,32(02):103-106.[doi:10.3969/j.issn.1006-1959.2019.02.029]
　ZENG Li-wen,CHEN Jing,ZHANG Ye,et al.Analysis of Characteristics of Glucose Metabolism in Patients with Polycystic Ovarian Syndrome[J].Journal of Medical Information,2019,32(02):103-106.[doi:10.3969/j.issn.1006-1959.2019.02.029]
点击复制

多囊卵巢综合征患者的糖代谢特点分析()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
32卷
期数:
2019年02期
页码:
103-106
栏目:
论著
出版日期:
2019-01-15

文章信息/Info

Title:
Analysis of Characteristics of Glucose Metabolism in Patients with Polycystic Ovarian Syndrome
文章编号:
1006-1959（2019）02-0103-04
作者:
曾利文1; 陈 静1; 张 晔2; 杨 雁2; 张建华2
1.泰康同济<武汉>医院内分泌科，湖北 武汉 430050；2.华中科技大学同济医学院附属同济医院内分泌科，湖北 武汉 430050
Author(s):
ZENG Li-wen1; CHEN Jing1; ZHANG Ye2; YANG Yan2; ZHANG Jian-hua2
1.Department of Endocrinology,Taikang TongjiHospital,Wuhan 430050,Hubei,China;2.Department of Endocrinology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430050,Hubei,China
关键词:
多囊卵巢综合征; 口服葡萄糖耐量试验; 肥胖; 年龄
Keywords:
Polycystic ovarian syndrome; Oral glucose tolerance test; Obesity; Age
分类号:
R711.75
DOI:
10.3969/j.issn.1006-1959.2019.02.029
文献标志码:
A
摘要:
目的 研究多囊卵巢综合征（PCOS）患者的糖代谢特征。方法 选择2014年1月~2018年3月我院收治的符合鹿特丹标准、未经治疗的PCOS患者935例，测定身高、体重，并行口服葡萄糖耐量试验（OGTT）和胰岛素释放试验（IRT），计算体重指数（BMI）、胰岛素抵抗稳态指数模型（HOMA-IR）、β细胞功能指数（HOMA-β）等参数。根据血糖水平将 PCOS 患者分为糖代谢正常（NGT）组、空腹血糖受损（IFG）组、糖耐量受损（IGT）组、混合型糖耐量受损（CGI）组及糖尿病（T2DM）组；根据体重指数
Abstract:
Objective To study the characteristics of glucose metabolism in patients with polycystic ovarian syndrome (PCOS).Methods From January 2014 to March 2018, 935 patients with Rotterdam-compliant and untreated PCOS were enrolled in our hospital. The height, weight, and oral glucose tolerance test (OGTT) and insulin release test (IRT) were calculated. Body mass index (BMI), insulin resistance homeostasis index model (HOMA-IR), β cell function index (HOMA-β) and other parameters. According to blood glucose levels, PCOS patients were divided into normal glucose metabolism (NGT) group, impaired fasting glucose (IFG) group, impaired glucose tolerance (IGT) group, mixed glucose tolerance (CGI) group and diabetes (T2DM) group. According to body mass index (BMI), it was divided into obese group and non-obese group; according to age, it was divided into puberty group and childbearing age group, and the differences of glucose metabolism in each group were compared.Results ①The incidence of IR in PCOS patients was 58.40% (n=546); the abnormal rate of glucose metabolism was 38.93% (n=364), of which IFG group accounted for 5.13%, IGT group accounted for 23.64%, CGI group accounted for 5.24%, T2DM group accounted for 4.92%.②The age, BMI, FPG, G60, G120, G180, HOMA-IR and HOMA-β of the PCOS obese group were higher than those of the non-obese group (P<0.01).③The age, FPG, G60 and G120 of the 3PCOS childbearing age group were higher than those of the puberty group (P<0.01). There was no significant difference in the BMI, G180 and HOMA-IR between the two groups (P>0.05).Conclusion The incidence of abnormal glucose metabolism is higher in PCOS patients, and the abnormal glucose metabolism is more serious in obese PCOS patients. Adolescence is characterized by insulin resistance and hyperinsulinemia, and the incidence of abnormal glucose metabolism increases with age.

参考文献/References:

[1]Elbohoty AE,Amer M,Abdelmoaz M.Clomiphene citrate before and after withdrawal bleeding for induction of ovulation in women with polycystic ovary syndrome: Randomized cross-over trial[J].Journal of Obstetrics & Gynaecology Research,2016,42(8):966-971.
[2]Fauser BC,Tarlatzis BC,Rebar RW,et al.Consensus on women′s health aspects of polycystic ovary syndrome(PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group[J].Fertil Steril,2012,97(1):28-38.
[3]Li R,Zhang Q,Yang D,et al.Prevalence of polycystic ovary syndrome in women in China: a large community-based study[J].Human Reproduction,2013,28(9):2562-2569.
[4]Mortada R,Williams T.Metabolic Syndrome:Polycystic Ovary Syndrome[J].Fp Essentials,2015(435):30.
[5]Chang J,Azziz R,Legro R,et al.The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group (2004) Revised 2003 consensus on diagnostic criteria and long-term healt h risks related to polycystic ovary syndrome[J] Fertility & Sterility,2004,81(1):19-25.
[6]Gheita TA,El-Fishawy HS,Nasrallah MM,et al.Insulin resistance and metabolic syndrome in primary gout: relation to punched-out erosions[J].International Journal of Rheumatic Diseases,2012,15(6):521-525.
[7]乔杰,李蓉,李莉,等.多囊卵巢综合征流行病学研究[J].中国实用妇科与产科杂志,2013(11):849-852.
[8]中国医师协会内分泌代谢科医师分会.多囊卵巢综合征诊治内分泌专家共识[J].中华内分泌代谢杂志,2018,34(1):1-7.
[9]Pasquali R,Gambineri A.Glucose intolerance states in women with the polycystic ovary syndrome[J].Journal of Endocrinological Investigation,2013,36(8):648-653.
[10]Morciano A,Romani F,Sagnella F,et al.Assessment of insulin resistance in lean women with polycystic ovary syndrome[J].Fertility & Sterility,2014,102(1):250-256.
[11]Pauli JM,Raja-Khan N,Wu X,et al.Current perspectives of insulin resistance and polycystic ovary syndrome[J].Diabetic Medicine,2011,28(12):1445.
[12]Nisenblat V,Norman RJ.Androgens and polycystic ovary syndrome[J].Current Opinion in Endocrinology Diabetes & Obesity,2009,16(3):224.
[13]吴香春.多囊卵巢综合征患者胰岛素抵抗的临床分析[J].中国性科学,2014(6):12-13.
[14]Asunción M,Calvo RM,San Millán JL,et al.A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain[J].J Clin Endocrinol Metab,2000,85(7):2434-2438.
[15]Makki K,Froguel P,Wolowczuk I.Adipose tissue in obesity-related in flammation and insulin resistance: cells, cytokines, and chemokines[J].ISRN Inflamm,2013(2013):139239.
[16]全国卫生产业企业管理协会妇幼健康产业分会生殖内分泌.青春期多囊卵巢综合征诊治共识[J].生殖医学杂志,2016,25(9):767-770.

相似文献/References:

[1]袁 奔,潘 伟,罗淑红,等.体重指数对多囊卵巢综合征患者 人工授精妊娠结局影响[J].医学信息,2018,31(12):99.[doi:10.3969/j.issn.1006-1959.2018.12.030]
　YUAN Ben,PAN Wei,LUO Shu-hong,et al.Effects of Body Mass Index on the Outcome of Artificial Insemination in Patients with Polycystic Ovary Syndrome[J].Journal of Medical Information,2018,31(02):99.[doi:10.3969/j.issn.1006-1959.2018.12.030]
[2]罗红财,沈 颖,黄莉珊,等.基于温肾助阳、暖宫温胞改善卵巢功能异常的机制分析[J].医学信息,2022,35(11):172.[doi:10.3969/j.issn.1006-1959.2022.11.046]
　LUO Hong-cai,SHEN Ying,HUANG Li-shan,et al.The Mechanism Analysis of Improve Symptoms Related to Ovarian Dysfunction Based on Warming Kidney and Helping Yang,Warming Baogong[J].Journal of Medical Information,2022,35(02):172.[doi:10.3969/j.issn.1006-1959.2022.11.046]
[3]李德君,李慧君.来曲唑联合苍附导痰汤治疗多囊卵巢综合征不孕症患者的 临床观察[J].医学信息,2018,31(17):137.[doi:10.3969/j.issn.1006-1959.2018.17.043]
　LI De-jun,LI Hui-jun.Clinical Observation of Letrozole Combined with Cangfu Daotan Decoction in the Treatment of Infertility Patients with Polycystic Ovary Syndrome[J].Journal of Medical Information,2018,31(02):137.[doi:10.3969/j.issn.1006-1959.2018.17.043]
[4]陈 丽,郝丽娟.多囊卵巢综合征患者腹型肥胖、高雄、胰岛素抵抗及脂代谢的相关性分析[J].医学信息,2022,35(12):113.[doi:10.3969/j.issn.1006-1959.2022.12.027]
　CHEN Li,HAO Li-juan.Correlation of Abdominal Obesity, Hyperandrogenism, Insulin Resistance and Lipid Metabolism in Patients with Polycystic Ovary Syndrome[J].Journal of Medical Information,2022,35(02):113.[doi:10.3969/j.issn.1006-1959.2022.12.027]
[5]左俊芳,刘沙沙,崔洪艳.妊娠期糖尿病高危因素及预防措施研究[J].医学信息,2022,35(17):177.[doi:10.3969/j.issn.1006-1959.2022.17.048]
　ZUO Jun-fang,LIU Sha-sha,CUI Hong-yan.Study on High Risk Factors and Preventive Measures of Gestational Diabetes Mellitus[J].Journal of Medical Information,2022,35(02):177.[doi:10.3969/j.issn.1006-1959.2022.17.048]
[6]谢 丹.不同促排卵方案治疗多囊卵巢综合征不孕症的效果[J].医学信息,2020,33(18):141.[doi:10.3969/j.issn.1006-1959.2020.18.046]
　XIE Dan.The Effect of Different Ovulation Induction Programs on the Infertility of Polycystic Ovary Syndrome[J].Journal of Medical Information,2020,33(02):141.[doi:10.3969/j.issn.1006-1959.2020.18.046]
[7]朱 艳,周 琴,安 洁,等.脂联素基因单核苷酸多态性与多囊卵巢综合征伴胰岛素抵抗的关系研究[J].医学信息,2020,33(22):87.[doi:10.3969/j.issn.1006-1959.2020.22.025]
　ZHU Yan,ZHOU Qin,AN Jie,et al.Study on the Relationship Between Adiponectin Gene Single Nucleotide Polymorphism and Polycystic Ovary Syndrome with Insulin Resistance[J].Journal of Medical Information,2020,33(02):87.[doi:10.3969/j.issn.1006-1959.2020.22.025]
[8]王海燕,毕雪玲,曹 晶,等.坤泰胶囊联合炔雌醇环丙孕酮片、二甲双胍治疗多囊卵巢综合征的效果及对性激素的影响[J].医学信息,2020,33(20):129.[doi:10.3969/j.issn.1006-1959.2020.20.039]
　WANG Hai-yan,BI Xue-ling,CAO Jing,et al.The Effect of Kuntai Capsule Combined with Ethinyl Estradiol and Cyproterone Tablets and Metformin in the Treatment of Polycystic Ovary Syndrome and Its Influence on Sex Hormones[J].Journal of Medical Information,2020,33(02):129.[doi:10.3969/j.issn.1006-1959.2020.20.039]
[9]王争艳,宋发荣.中药月经周期疗法治疗PCOS不孕症的效果[J].医学信息,2020,33(20):153.[doi:10.3969/j.issn.1006-1959.2020.20.048]
　WANG Zheng-yan,SONG Fa-rong.The Effect of Chinese Medicine Menstrual Cycle Therapy on PCOS Infertility[J].Journal of Medical Information,2020,33(02):153.[doi:10.3969/j.issn.1006-1959.2020.20.048]
[10]袁 瑞,余亚莉.吡格列酮二甲双胍片治疗胰岛素抵抗型多囊卵巢综合征患者的疗效[J].医学信息,2021,34(01):158.[doi:10.3969/j.issn.1006-1959.2021.01.043]
　YUAN Rui,YU Ya-li.Efficacy of Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets in the Treatment of Patients with Insulin-resistant Polycystic Ovary Syndrome[J].Journal of Medical Information,2021,34(02):158.[doi:10.3969/j.issn.1006-1959.2021.01.043]

更新日期/Last Update: 2019-02-15